A Phase 1 interventional study of BIIB145 and Placebo in Healthy Volunteer, sponsored by Biogen. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by Biogen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In this study, researchers will learn for the first time about the safety of a study drug called BIIB145 and how the body responds to it. This is a "Phase 1" study. This kind of study is an early step in clinical research where the goal is to focus on the safety of the study drug. Another goal may be to learn how the study drug is processed by the body. BIIB145 was designed to help people with multiple sclerosis (MS). But, before it can be tested in people with MS, it must first be tested in healthy volunteers to learn about its safety and other effects.
The main goal of this study is to learn about the safety of BIIB145 and how it is processed by the body, with or without food.
The main questions researchers want to answer are:
Researchers will also learn more about:
This study will be done as follows:
The primary objective of the study is to evaluate the safety and tolerability of single and multiple ascending doses of BIIB145 in healthy adult participants.
The secondary objectives of the study are to evaluate the pharmacokinetics (PK) profile of single and multiple ascending doses of BIIB145 and its enantiomers in healthy adult participants; and the effect of food on the PK profile of BIIB145.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Dose A of BIIB145 or a matching placebo on Day 1 in a fasted state.
Drug: BIIB145 · Drug: Placebo
Participants will receive Dose B of BIIB145 or a matching placebo on Day 1 in a fasted state.
Drug: BIIB145 · Drug: Placebo
Participants will receive Dose C of BIIB145 or a matching placebo on Day 1 in a fasted state.
Drug: BIIB145 · Drug: Placebo
Participants will receive Dose D of BIIB145 or a matching placebo on Day 1 in a fasted state.
Drug: BIIB145 · Drug: Placebo
Participants will receive Dose E of BIIB145 or a matching placebo on Day 1 in a fasted state.
Drug: BIIB145 · Drug: Placebo
Participants will receive Dose F of BIIB145 or a matching placebo on Day 1 in a fasted state.
Drug: BIIB145 · Drug: Placebo
Participants will receive Dose G of BIIB145 or a matching placebo on Day 1 in a fasted state.
Drug: BIIB145 · Drug: Placebo
Participants will receive BIIB145 on Day 1 in the fasted state, followed by the fed state in the first sequence, and vice versa in the second sequence. A washout period of 7 days will be maintained between the two sequences. Dose will be determined based on safety and PK data of SAD Cohort 6A as well as safety, PK and pharmacodynamics (PD) data from previous cohorts.
Drug: BIIB145
Participants will receive Dose B of BIIB145 or a matching placebo administered orally once daily for 14 days in a fasted state.
Drug: BIIB145 · Drug: Placebo
Participants will receive Dose C of BIIB145 or a matching placebo administered orally once daily for 14 days in a fasted state.
Drug: BIIB145 · Drug: Placebo
Participants will receive Dose H of BIIB145 or a matching placebo administered orally once daily for 14 days in a fasted state.
Drug: BIIB145 · Drug: Placebo
Participants will receive Dose F of BIIB145 or a matching placebo administered orally once daily for 14 days in a fasted state.
Drug: BIIB145 · Drug: Placebo
Administered orally
Administered orally
Parts A, B, and C: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Parts A and Part B: Up to Day 14; Part C: Up to Day 28
Parts A, B, and C: Number of Participants With Clinical Laboratory Abnormalities
Time frame: Parts A and Part B: Up to Day 14; Part C: Up to Day 28
Parts A, B, and C: Number of Participants With Clinically Relevant Abnormalities in Vital Sign Parameters
Time frame: Parts A and Part B: Up to Day 14; Part C: Up to Day 28
Part C: Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Events
Time frame: Part C: Up to Day 28
Parts A, B, and C: Number of Participants With Potentially Clinically Relevant Abnormalities in 12-lead Electrocardiogram (ECG) Parameters
Time frame: Parts A and B: Up to Day 14; Part C: Up to Day 28
Parts A, B, and C: Area Under the Concentration-Time Curve (AUC) of BIIB145
Time frame: Pre-dose and at multiple timepoints post-dose (Parts A and B: Up to Day 4; Part C: Up to Day 17)
Parts A, B, and C: Maximum Observed Concentration (Cmax) of BIIB145
Time frame: Pre-dose and at multiple timepoints post-dose (Parts A and B: Up to Day 4; Part C: Up to Day 17)
Parts A, B, and C: Time to Maximum Observed Concentration (Tmax) of BIIB145
Time frame: Pre-dose and at multiple timepoints post-dose (Parts A and B: Up to Day 4; Part C: Up to Day 17)
Parts A, B, and C: Elimination Half-Life (t1/2) of BIIB145
Time frame: Pre-dose and at multiple timepoints post-dose (Parts A and B: Up to Day 4; Part C: Up to Day 17)
Parts A, B, and C: Apparent Clearance (CL/F) of BIIB145
Time frame: Pre-dose and at multiple timepoints post-dose (Parts A and B: Up to Day 4; Part C: Up to Day 17)
Parts A, B, and C: Apparent Volume of Distribution (Vz/F) of BIIB145
Time frame: Pre-dose and at multiple timepoints post-dose (Parts A and B: Up to Day 4; Part C: Up to Day 17)
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Feb 2027, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.